These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15068491)

  • 1. Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone.
    Salmon P
    J Bone Miner Res; 2004 May; 19(5):695-702. PubMed ID: 15068491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
    Middleton-Hardie C; Zhu Q; Cundy H; Lin JM; Callon K; Tong PC; Xu J; Grey A; Cornish J; Naot D
    J Bone Miner Res; 2006 Mar; 21(3):438-45. PubMed ID: 16491292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin deficiency and juvenile Paget's disease.
    Whyte MP; Obrecht SE; Finnegan PM; Jones JL; Podgornik MN; McAlister WH; Mumm S
    N Engl J Med; 2002 Jul; 347(3):175-84. PubMed ID: 12124406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels.
    Whyte MP; Singhellakis PN; Petersen MB; Davies M; Totty WG; Mumm S
    J Bone Miner Res; 2007 Jun; 22(6):938-46. PubMed ID: 17352649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
    Whyte MP
    Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
    Ueland T; Bollerslev J; Mosekilde L
    Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
    Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of OPG in regulation of bone remodeling].
    Nakamichi Y; Udagawa N
    Clin Calcium; 2006 Sep; 16(9):1463-68. PubMed ID: 16951469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
    Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.